This site is intended for Healthcare professionals only.

Halobetasol propionate safe,effective treatment of psoriasis


Halobetasol propionate safe,effective treatment of psoriasis

A new study published in Journal of Drugs in Dermatology reports that Halobetasol propionate 0.01 percent lotion (BRYHALI Lotion) appears safe and effective for the treatment of moderate-to-severe plaque psoriasis.

Lawrence J. Green and associates conducted a study to investigate the safety and efficacy of halobetasol propionate 0.01% lotion in moderate-to-severe plaque psoriasis.

Read Also: Alternative medicine therapies found effective in Psoriasis : JAMA
The investigators conducted two multicentered, randomized, double-blind, vehicle-controlled phase 3 studies (N=430) where the study participants were randomized (2:1) to halobetasol propionate 0.01% lotion or vehicle once-daily for 8 weeks, 4-week posttreatment follow-up.

Key study findings:

  • Halobetasol propionate 0.01% lotion demonstrated statistically significant superiority over the vehicle as early as week 2.
  • By week 8, 36.5% (Study 1) and 38.4% (Study 2) of subjects were treatment successes compared with 8.1% and 12.0% on the vehicle.
  • Halobetasol propionate 0.01% lotion was also superior in reducing psoriasis signs and symptoms, body surface area (BSA), and improving quality of life.
  • Halobetasol propionate 0.01% lotion was well-tolerated with no treatment-related AEs greater than 1%.

Read Also: Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis-Phase 3 Trial Report

The study concluded that Halobetasol propionate 0.01% lotion was associated with significant reductions in the severity of the clinical signs of psoriasis, without the safety concerns of a longer treatment course.

Psoriasis is a chronic, immune-mediated disease that affects approximately 2% of the population. The use of topical therapy is a key component in the management of almost all psoriasis patients. Topicals are considered first-line therapy for mild disease and are having an increasing role in moderate-to-severe psoriasis. The use of topical corticosteroids (TCS) is commonplace, mainly due to their immunosuppressive, anti-inflammatory, and anti-proliferative properties.

For reference log on to http://jddonline.com/articles/dermatology/S1545961618P1062X/1

The following two tabs change content below.
Vinay Singh

Vinay Singh

Vinay Singh joined Medical Dialogue as Desk Editor in 2018. He covers all the medical specialty news in different medical categories. He also covers the Medical guidelines, Medical Journals, Case Reports as well as all the updates in the medical field. He completed his graduation in Biotechnology from AAIDU and did his MBA from IILM Gurgaon. He can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Source: With inputs from the Journal of Drugs in Dermatology

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted